Compare EXEL & SEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXEL | SEIC |
|---|---|---|
| Founded | 1994 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.8B |
| IPO Year | 2000 | 1995 |
| Metric | EXEL | SEIC |
|---|---|---|
| Price | $45.92 | $83.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 7 |
| Target Price | $46.50 | ★ $102.29 |
| AVG Volume (30 Days) | ★ 2.0M | 821.2K |
| Earning Date | 05-12-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.28% |
| EPS Growth | ★ 57.95 | 27.66 |
| EPS | 2.78 | ★ 5.63 |
| Revenue | $452,477,000.00 | ★ $2,297,381,000.00 |
| Revenue This Year | $13.61 | $14.61 |
| Revenue Next Year | $13.13 | $7.25 |
| P/E Ratio | $15.73 | ★ $14.47 |
| Revenue Growth | N/A | ★ 8.10 |
| 52 Week Low | $33.76 | $72.21 |
| 52 Week High | $48.74 | $93.96 |
| Indicator | EXEL | SEIC |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 64.50 |
| Support Level | $40.53 | $82.87 |
| Resistance Level | $46.46 | $84.05 |
| Average True Range (ATR) | 1.22 | 1.78 |
| MACD | 0.10 | 0.72 |
| Stochastic Oscillator | 95.00 | 94.38 |
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $99 billion in assets under management. As of December 2025, SEI (including LSV) manages, administers, or advises about $1.9 trillion in assets.